Vaxart Inc VXRT

NAS: VXRT | ISIN: US92243A2006   30/04/2025
0,440 USD (+3,39%)
(+3,39%)   30/04/2025

27 juli 2022 · Vaxart fournit une nouvelle mise à jour sur les votes par procuration et exhorte tous les actionnaires inscrits au 11 avril 2022 à voter avant le 3 août 2022 à 23h59 (heure de l'Est) · Persbericht

27 juli 2022 · Vaxart biedt nieuwe update over stemmen bij volmacht en dringt er bij alle op 11 april 2022 geregistreerde aandeelhouders op aan om vóór 3 augustus 2022 om 23:59 uur ET te stemmen · Persbericht

27 juli 2022 · Vaxart Provides New Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022, to Vote by August 3, 2022, at 11:59 p.m. ET · Persbericht

26 oktober 2021 · Vaxart Doses First Subject in Phase II COVID-19 Oral Tablet Vaccine Clinical Trial · Persbericht

7 oktober 2021 · New Duke University-led Study Shows That Vaxart's Oral COVID-19 Vaccine Candidate Reduces Airborne Transmission of SARS-CoV-2 Infection in Animal Model · Persbericht

6 oktober 2021 · Vaxart Begins Recruiting in Global Phase II COVID-19 Oral Tablet Vaccine Clinical Trial · Persbericht

27 september 2021 · Vaxart Appoints Dr. James F. Cummings as Chief Medical Officer · Persbericht

22 september 2021 · Vaxart To Present at Upcoming Vaccine Conferences · Persbericht

21 september 2021 · Vaxart Announces Creation of Manufacturing and Quality Advisory Board · Persbericht

20 september 2021 · Vaxart to Present at the 2021 Cantor Virtual Global Healthcare Conference on Thursday, September 30 · Persbericht

7 september 2021 · Vaxart to Present at the H.C. Wainwright 23rd Annual Global Investment Conference · Persbericht

23 augustus 2021 · Vaxart Announces Highly Regarded Biotech Executive Julie M. Cherrington, Ph.D., Joins Board of Directors · Persbericht

19 augustus 2021 · Vaxart Announces Creation of New Scientific and Clinical Advisory Board · Persbericht

5 augustus 2021 · Vaxart Provides Business Update and Reports Second Quarter 2021 Financial Results · Persbericht

2 augustus 2021 · FDA Clears Vaxart's IND Application for S-Only Oral Tablet COVID-19 Vaccine Candidate · Persbericht

29 juli 2021 · Vaxart Reports Boosting Immune Responses in Subjects Previously Vaccinated by a Vaxart Vaccine · Persbericht

4 maart 2021 · Vaxart to Present at the H.C. Wainwright Global Life Sciences Conference · Persbericht

24 februari 2021 · Vaxart to Provide 2021 Business Outlook on Tuesday, March 2, 2021 · Persbericht

3 februari 2021 · Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate · Persbericht

27 januari 2021 · Vaxart Announces Publication of a Peer-reviewed Journal Article Showing the Potential Clinical and Economic Value of a Norovirus Vaccine · Persbericht

Mijn selecties